Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases

Renate M Hoogeveen; Matthias Nahrendorf; Niels P Riksen; Mihai G Netea; Menno P J de Winther; Esther Lutgens; Børge G Nordestgaard; Michel Neidhart; Erik S G Stroes; Alberico L Catapano; Siroon Bekkering

doi:10.1093/eurheartj/ehx581

Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases

Renate M Hoogeveen, Matthias Nahrendorf, Niels P Riksen, Mihai G Netea, Menno P J de Winther, Esther Lutgens, Børge G Nordestgaard, Michel Neidhart, Erik S G Stroes, Alberico L Catapano, Siroon Bekkering

Institut for Klinisk Medicin

30 Citationer (Scopus)

30 Downloads (Pure)

Abstract

A large number of cardiovascular events are not prevented by current therapeutic regimens. In search for additional, innovative strategies, immune cells have been recognized as key players contributing to atherosclerotic plaque progression and destabilization. Particularly the role of innate immune cells is of major interest, following the recent paradigm shift that innate immunity, long considered to be incapable of learning, does exhibit immunological memory mediated via epigenetic reprogramming. Compelling evidence shows that atherosclerotic risk factors promote immune cell migration by pre-activation of circulating innate immune cells. Innate immune cell activation via metabolic and epigenetic reprogramming perpetuates a systemic low-grade inflammatory state in cardiovascular disease (CVD) that is also common in other chronic inflammatory disorders. This opens a new therapeutic area in which metabolic or epigenetic modulation of innate immune cells may result in decreased systemic chronic inflammation, alleviating CVD, and its co-morbidities.

Originalsprog	Engelsk
Tidsskrift	European Heart Journal
Vol/bind	39
Udgave nummer	38
Sider (fra-til)	3521-3527
Antal sider	7
ISSN	0195-668X
DOI	https://doi.org/10.1093/eurheartj/ehx581
Status	Udgivet - 7 okt. 2018

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1093/eurheartj/ehx581Licens: CC BY-NC

Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseasesForlagets udgivne version, 497 KBLicens: CC BY-NC

Citationsformater

Hoogeveen, R. M., Nahrendorf, M., Riksen, N. P., Netea, M. G., de Winther, M. P. J., Lutgens, E., Nordestgaard, B. G., Neidhart, M., Stroes, E. S. G., Catapano, A. L., & Bekkering, S. (2018). Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases. European Heart Journal, 39(38), 3521-3527. https://doi.org/10.1093/eurheartj/ehx581

Hoogeveen, RM, Nahrendorf, M, Riksen, NP, Netea, MG, de Winther, MPJ, Lutgens, E, Nordestgaard, BG, Neidhart, M, Stroes, ESG, Catapano, AL & Bekkering, S 2018, 'Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases', European Heart Journal, bind 39, nr. 38, s. 3521-3527. https://doi.org/10.1093/eurheartj/ehx581

@article{5187c41e0b8948b78bac65605526bae5,

title = "Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases",

abstract = "A large number of cardiovascular events are not prevented by current therapeutic regimens. In search for additional, innovative strategies, immune cells have been recognized as key players contributing to atherosclerotic plaque progression and destabilization. Particularly the role of innate immune cells is of major interest, following the recent paradigm shift that innate immunity, long considered to be incapable of learning, does exhibit immunological memory mediated via epigenetic reprogramming. Compelling evidence shows that atherosclerotic risk factors promote immune cell migration by pre-activation of circulating innate immune cells. Innate immune cell activation via metabolic and epigenetic reprogramming perpetuates a systemic low-grade inflammatory state in cardiovascular disease (CVD) that is also common in other chronic inflammatory disorders. This opens a new therapeutic area in which metabolic or epigenetic modulation of innate immune cells may result in decreased systemic chronic inflammation, alleviating CVD, and its co-morbidities.",

author = "Hoogeveen, {Renate M} and Matthias Nahrendorf and Riksen, {Niels P} and Netea, {Mihai G} and {de Winther}, {Menno P J} and Esther Lutgens and Nordestgaard, {B{\o}rge G} and Michel Neidhart and Stroes, {Erik S G} and Catapano, {Alberico L} and Siroon Bekkering",

year = "2018",

month = oct,

day = "7",

doi = "10.1093/eurheartj/ehx581",

language = "English",

volume = "39",

pages = "3521--3527",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "38",

}

TY - JOUR

T1 - Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases

AU - Hoogeveen, Renate M

AU - Nahrendorf, Matthias

AU - Riksen, Niels P

AU - Netea, Mihai G

AU - de Winther, Menno P J

AU - Lutgens, Esther

AU - Nordestgaard, Børge G

AU - Neidhart, Michel

AU - Stroes, Erik S G

AU - Catapano, Alberico L

AU - Bekkering, Siroon

PY - 2018/10/7

Y1 - 2018/10/7

N2 - A large number of cardiovascular events are not prevented by current therapeutic regimens. In search for additional, innovative strategies, immune cells have been recognized as key players contributing to atherosclerotic plaque progression and destabilization. Particularly the role of innate immune cells is of major interest, following the recent paradigm shift that innate immunity, long considered to be incapable of learning, does exhibit immunological memory mediated via epigenetic reprogramming. Compelling evidence shows that atherosclerotic risk factors promote immune cell migration by pre-activation of circulating innate immune cells. Innate immune cell activation via metabolic and epigenetic reprogramming perpetuates a systemic low-grade inflammatory state in cardiovascular disease (CVD) that is also common in other chronic inflammatory disorders. This opens a new therapeutic area in which metabolic or epigenetic modulation of innate immune cells may result in decreased systemic chronic inflammation, alleviating CVD, and its co-morbidities.

AB - A large number of cardiovascular events are not prevented by current therapeutic regimens. In search for additional, innovative strategies, immune cells have been recognized as key players contributing to atherosclerotic plaque progression and destabilization. Particularly the role of innate immune cells is of major interest, following the recent paradigm shift that innate immunity, long considered to be incapable of learning, does exhibit immunological memory mediated via epigenetic reprogramming. Compelling evidence shows that atherosclerotic risk factors promote immune cell migration by pre-activation of circulating innate immune cells. Innate immune cell activation via metabolic and epigenetic reprogramming perpetuates a systemic low-grade inflammatory state in cardiovascular disease (CVD) that is also common in other chronic inflammatory disorders. This opens a new therapeutic area in which metabolic or epigenetic modulation of innate immune cells may result in decreased systemic chronic inflammation, alleviating CVD, and its co-morbidities.

U2 - 10.1093/eurheartj/ehx581

DO - 10.1093/eurheartj/ehx581

M3 - Review

C2 - 29069365

SN - 0195-668X

VL - 39

SP - 3521

EP - 3527

JO - European Heart Journal

JF - European Heart Journal

IS - 38

ER -

Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater